Improving Treatments - Improving Lives
Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients and subsequent commercialization. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed.
To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 96780245
Following the conference call, a recording will be available on http://www.veloxis.com